Drug intelligence / Profile preview

lutetium (177Lu) lilotomab satetraxetan

Development stage: Phase 2
Lead developer: Nordic Nanovector
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lutetium (177Lu) lilotomab satetraxetan is a radioimmunotherapy agent consisting of lilotomab, a murine IgG1 monoclonal antibody targeting the CD37 antigen, conjugated to the chelating agent satetraxetan and radiolabeled with the beta-emitting isotope lutetium-177. Upon administration, the antibody moiety binds to CD37 expressed on B-cell lymphomas, delivering targeted beta radiation to tumor cells with the intent of antineoplastic activity. It is primarily under investigation for relapsed or refractory follicular lymphoma, marginal zone lymphoma, and other non-Hodgkin lymphoma subtypes in patients with limited treatment options, especially those refractory to anti-CD20 therapies[3][5][6][8].

Brand names: Betalutin
Other names: lutetium Lu 177 lilotomab satetraxetan

Targets

CD37

Beyond the preview

Go deeper on lutetium (177Lu) lilotomab satetraxetan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium (177Lu) lilotomab satetraxetan.

Explore the full profile